Faecal Microbiota Transplantation for Liver Cirrhosis
Faecal Microbiota Transplantation to Prevent Complications, Progression and Mortality of Liver Cirrhosis
University of Aarhus
220 participants
Jul 1, 2021
INTERVENTIONAL
Conditions
Summary
The purpose is to investigate the effect of faecal microbiota transplantation (FMT) on complications, progression, and mortality of patients with liver cirrhosis. Further, the investigators want to examine the impact of FMT on the gut microbiota, gut barrier function, systemic inflammation, and immune function.
Eligibility
Inclusion Criteria3
- Age 18-75 years
- Liver cirrhosis with Child-Pugh ≤ 12
- Acute decompensation requiring intervention (ascites, gastrointestinal bleeding, infections leading to progressive liver failure, overthepatic encephalopathy, alcoholic hepatitis)
Exclusion Criteria9
- More than one organ failure defined by CLIF-SOFA score
- Untreated malignancy apart from non-melanoma skin cancer
- Untreated viral hepatitis
- HIV
- Inflammatory bowel disease
- Celiac disease
- Clostridioides Difficile infection
- Pregnancy
- Unable to participate based on medical judgement
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
All participant will receive three applications of either FMT or placebo and afterwards followed for 1 year.
Placebo
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04932577